Your browser doesn't support javascript.
Interleukin-17A (IL-17A): A silent amplifier of COVID-19.
Maione, Francesco; Casillo, Gian Marco; Raucci, Federica; Salvatore, Cristian; Ambrosini, Giovanna; Costa, Luisa; Scarpa, Raffaele; Caso, Francesco; Bucci, Mariarosaria.
  • Maione F; Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy.
  • Casillo GM; Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy.
  • Raucci F; Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy.
  • Salvatore C; New.Fa.DEm SRL, Viale Ferrovie Dello Stato, 1, 80014 Giugliano in Campania, Naples, Italy.
  • Ambrosini G; New.Fa.DEm SRL, Viale Ferrovie Dello Stato, 1, 80014 Giugliano in Campania, Naples, Italy.
  • Costa L; Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy.
  • Scarpa R; Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy.
  • Caso F; Department of Clinical Medicine and Surgery, School of Medicine and Surgery, University of Naples Federico II, Via Sergio Pansini, 5, 80131 Naples, Italy. Electronic address: francesco.caso@unina.it.
  • Bucci M; Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131 Naples, Italy. Electronic address: mrbucci@unina.it.
Biomed Pharmacother ; 142: 111980, 2021 Oct.
Article in English | MEDLINE | ID: covidwho-1330664
ABSTRACT
One of the hallmarks of COVID-19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. Emerging evidence has identified a potential link between elevated interleukin-17A (IL-17A) levels and disease severity and progression. Considering that per se, IL-17A can activate several inflammatory pathways, it is plausible to hypothesize an involvement of this cytokine in COVID-19 clinical outcomes. Thus, IL-17A could represent a marker of disease progression and/or a target to develop therapeutic strategies. This hypothesis paper aims to propose this "unique" cytokine as a silent amplifier of the COVID-19 immune response and (potentially) related therapy.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-17 / Cytokine Release Syndrome / COVID-19 / COVID-19 Drug Treatment Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2021 Document Type: Article Affiliation country: J.biopha.2021.111980

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-17 / Cytokine Release Syndrome / COVID-19 / COVID-19 Drug Treatment Type of study: Diagnostic study / Prognostic study Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2021 Document Type: Article Affiliation country: J.biopha.2021.111980